Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2025-12-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $6.2B | $6.2B | $5.8B | $5.5B | $5.2B | $5.2B | $4.6B | $5.1B | $4.9B | $4.8B | $4.7B | $4.6B | $4.6B | $4.4B | $4.1B | $4.3B | $4.0B | $3.8B | $3.8B | $3.4B | $2.8B |
| Bruttoergebnis | $4.2B | $4.2B | $4.1B | $3.9B | $3.7B | $3.7B | $3.2B | $3.8B | $3.6B | $3.5B | $3.4B | $3.5B | $3.5B | $3.3B | $3.1B | $3.1B | $2.9B | $2.7B | $2.7B | $2.4B | $2.0B |
| Bruttomarge % | 68.2% | 68.2% | 70.2% | 70.2% | 71.0% | 71.0% | 69.7% | 74.1% | 73.5% | 73.8% | 72.8% | 75.3% | 75.6% | 75.1% | 74.1% | 73.3% | 74.0% | 72.7% | 71.7% | 70.5% | 72.3% |
| Betriebsergebnis (EBIT) | $794M | $794M | $657M | $425M | $450M | $593M | $295M | $815M | $863M | $934M | $801M | $628M | $749M | $810M | $846M | $862M | $920M | $723M | $630M | $493M | $537M |
| Operative Marge % | 12.9% | 12.9% | 11.3% | 7.7% | 8.6% | 11.4% | 6.5% | 15.9% | 17.6% | 19.6% | 17.2% | 13.6% | 16.2% | 18.6% | 20.4% | 20.2% | 23.2% | 19.2% | 16.6% | 14.6% | 19.3% |
| Jahresüberschuss | $625M | $625M | $412M | $263M | $223M | $524M | $448M | $600M | $663M | $767M | $784M | $410M | $501M | $556M | $729M | $582M | $615M | $472M | $377M | $316M | $745M |
| Nettomarge % | 10.1% | 10.1% | 7.1% | 4.7% | 4.3% | 10.1% | 9.8% | 11.7% | 13.5% | 16.1% | 16.8% | 8.8% | 10.8% | 12.8% | 17.6% | 13.6% | 15.5% | 12.5% | 9.9% | 9.4% | 26.8% |
| EBITDA | $1.3B | $1.3B | $1.3B | $1.2B | $1.1B | $1.2B | $927M | $1.4B | $1.4B | $1.3B | $1.3B | $1.2B | $1.3B | $1.2B | $1.2B | $1.2B | $1.2B | $1.0B | $910M | $721M | $703M |
| Ergebnis je Aktie (EPS) | $1.43 | $1.43 | $0.94 | $1.20 | $0.51 | $1.19 | $1.02 | $1.37 | $1.52 | $1.75 | $1.76 | $0.94 | $1.11 | $1.23 | $1.62 | $1.30 | $1.38 | $1.07 | $0.85 | $0.68 | $1.58 |
| Ausstehende Aktien (Mio.) | 436M | 436M | 438M | 218M | 438M | 439M | 438M | 438M | 438M | 438M | 446M | 436M | 450M | 453M | 450M | 448M | 444M | 443M | 445M | 464M | 472M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für SNN. /companies/us/SNN
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms